ReviewAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2023
Genetically Engineered-Cell-Membrane Nanovesicles for Cancer Immunotherapy.
Review in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed.
- New insights into breast cancer therapy: application and mechanisms of novel targeted nano-formulation.International journal of pharmaceutics: X · 2026Review
- Precisely Engineering Biomimetic Nanoparticles via Controlled Cell Membrane Coating.Small (Weinheim an der Bergstrasse, Germany) · 2026Review
- Sprayable hydrogel loaded with engineered fusion cellular vesicles for cancer recurrence suppression.Journal of nanobiotechnology · 2026Article
- Personalized cancer vaccines: bridging immune-oncology and precision medicine for advanced therapeutics.Signal transduction and targeted therapy · 2026Review
- Chemokine-Guided Biomimetic Mn/Ce Nanozymes for Immunomodulation and Cardioprotection in Doxorubicin-Induced Cardiomyopathy.Advanced healthcare materials · 2026Article
- Immune-Evasive Biomimetic Gold-Carbon Nanoplatform for Dual-Modal Theranostics of Hepatocellular Carcinoma.Small methods · 2026Article
- A biomimetic nanointegrator synergizing "dual-throttle" immune checkpoint blockade and enhanced DAMPs-mediated immune activation for potent anti-tumor T‑cell immunity.Journal of nanobiotechnology · 2026Article
- Hybrid membrane-camouflaged photothermal immunomodulatory nanoparticle inhibits colorectal cancer growth and metastasis.International journal of pharmaceutics: X · 2026Article
- Biomimetic nanovesicles and nanotechnology for oral and maxillofacial diseases.Discover nano · 2026Review
- Biomimetic Cell Membrane-Coated MOFs System for Targeted Cancer Therapy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Review
- Membrane-derived biomimetic nanovesicles in anti-tumor immunotherapy: Advances and outlook.Acta pharmaceutica Sinica. B · 2026Review
- Incorporation of Functional Proteins on Cellular Surfaces via Artificial Cell-Derived Vesicles (ACDVs) for Plasma Membrane Reprogramming.Journal of the American Chemical Society · 2026Article
- Cell membrane biomimetic nanoplatforms: a new strategy for immune escape and precision targeted therapy.Materials today. Bio · 2025Review
- Article
- Stealth missiles with precision guidance: A novel multifunctional nano-drug delivery system based on biomimetic cell membrane coating technology.Materials today. Bio · 2025Review
- piR-RCC Suppresses Renal Cell Carcinoma Progression by Facilitating YBX-1 Cytoplasm Localization.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Material-Driven Therapeutics: Functional Nanomaterial Design Paradigms Revolutionizing Osteosarcoma Treatment.Journal of functional biomaterials · 2025Review
- A Bionic "Trojan Horse"-like Nanovesicle Delivery System Hybridized with BCG Cytoplasmic Membrane and Melanoma Cell Membrane for Cancer Immunotherapy.Pharmaceutics · 2025Article
- Cell membrane-derived nanovesicles as extracellular vesicle-mimetics in wound healing.Materials today. Bio · 2025Review
- Inhalable nanovesicles loaded with a STING agonist enhance CAR-T cell activity against solid tumors in the lung.Nature communications · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
The advent of immunotherapy has marked a new era in cancer treatment, offering significant clinical benefits. Cell membrane as drug delivery materials has played a crucial role in enhancing cancer therapy because of their inherent biocompatibility and negligible immunogenicity. Different cell membranes are prepared into cell membrane nanovesicles (CMNs), but CMNs have limitations such as inefficient targeting ability, low efficacy, and unpredictable side effects. Genetic engineering has deepened the critical role of CMNs in cancer immunotherapy, enabling genetically engineered-CMN (GCMN)-based therapeutics. To date, CMNs that are surface modified by various functional proteins have been developed through genetic engineering. Herein, a brief overview of surface engineering strategies for CMNs and the features of various membrane sources is discussed, followed by a description of GCMN preparation methods. The application of GCMNs in cancer immunotherapy directed at different immune targets is addressed as are the challenges and prospects of GCMNs in clinical translation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.